MXPA03003322A - Subunidad de alfa de la beta2 integrina humana novedosa. - Google Patents

Subunidad de alfa de la beta2 integrina humana novedosa.

Info

Publication number
MXPA03003322A
MXPA03003322A MXPA03003322A MXPA03003322A MXPA03003322A MX PA03003322 A MXPA03003322 A MX PA03003322A MX PA03003322 A MXPA03003322 A MX PA03003322A MX PA03003322 A MXPA03003322 A MX PA03003322A MX PA03003322 A MXPA03003322 A MX PA03003322A
Authority
MX
Mexico
Prior art keywords
bgr
alpha subunit
novel human
integrin alpha
integrin
Prior art date
Application number
MXPA03003322A
Other languages
English (en)
Inventor
W Michael Gallatin
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of MXPA03003322A publication Critical patent/MXPA03003322A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
MXPA03003322A 2000-10-13 2001-10-15 Subunidad de alfa de la beta2 integrina humana novedosa. MXPA03003322A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/688,307 US6432404B1 (en) 1993-12-23 2000-10-13 Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies
PCT/US2001/032059 WO2002030980A2 (en) 2000-10-13 2001-10-15 Use of anti-human integrin alpha d antibodies to treat spinal cord injury

Publications (1)

Publication Number Publication Date
MXPA03003322A true MXPA03003322A (es) 2003-08-01

Family

ID=24763905

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003322A MXPA03003322A (es) 2000-10-13 2001-10-15 Subunidad de alfa de la beta2 integrina humana novedosa.

Country Status (10)

Country Link
US (1) US6432404B1 (es)
EP (1) EP1325031A2 (es)
JP (1) JP2004532800A (es)
KR (1) KR20030044001A (es)
CN (1) CN100398152C (es)
AU (2) AU9683901A (es)
CA (1) CA2425818A1 (es)
MX (1) MXPA03003322A (es)
NZ (1) NZ525402A (es)
WO (1) WO2002030980A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251395B1 (en) * 1993-12-23 2001-06-26 W. Michael Gallatin Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies
US20060115473A1 (en) * 2000-12-14 2006-06-01 Biogen Idec Ma Inc., A Massachusetts Corporation Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7737250B2 (en) * 2003-06-19 2010-06-15 Mount Sinai School Of Medicine Of New York University Peptides for treating axonal damage, inhibition of neurotransmitter release and pain transmission, and blocking calcium influx in neurons
US20070092515A1 (en) * 2003-11-06 2007-04-26 Icos Corporation Methods of treating chronic pain using compositions that specifically bind cd11d (alpha-d) integrin
US20050255098A1 (en) * 2004-05-11 2005-11-17 Rosen Steven D Methods of treating traumatic spinal cord injury
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CA2587597A1 (en) * 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Treatment for multiple sclerosis
EP1738763A1 (en) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
US20070004625A1 (en) * 2005-06-30 2007-01-04 Li Liang-Man Use of complement inhibitory proteins to treat spinal cord injury
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
CA2643496C (en) * 2008-11-06 2015-02-03 Michael Fehlings The therapeutic use of igg as a neuroprotective agent
DK3912643T3 (da) 2009-02-13 2022-10-17 Immunomedics Inc Immunokonjugater med en intracellulært-spaltelig binding
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
AU2010236257A1 (en) * 2009-04-17 2011-11-03 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
WO2011068845A1 (en) 2009-12-02 2011-06-09 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
LT2558499T (lt) 2010-04-16 2017-07-25 Biogen Ma Inc. Antikūnai prieš vla-4
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
CN103501825B (zh) 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN118001422A (zh) 2012-12-13 2024-05-10 免疫医疗公司 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN106132436B (zh) 2014-02-21 2021-06-15 Ibc药品公司 通过诱导对trop-2表达细胞的免疫应答的疾病疗法
EP3110445A4 (en) 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CA2953567C (en) 2014-06-24 2023-09-05 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
ES2953441T3 (es) 2015-06-25 2023-11-13 Immunomedics Inc Combinación de anticuerpos anti-hla-dr o anti-Trop-2 con inhibidores de microtúbulos, inhibidores de parp, inhibidores de la cinasa de bruton o inhibidores de la fosfoinositida 3-cinasa mejora significativamente el resultado terapéutico en el cáncer
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271139A (en) 1978-03-27 1981-06-02 Hiram Hart Scintillation proximity assay
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US6251395B1 (en) * 1993-12-23 2001-06-26 W. Michael Gallatin Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit

Also Published As

Publication number Publication date
EP1325031A2 (en) 2003-07-09
CN100398152C (zh) 2008-07-02
CN1589152A (zh) 2005-03-02
AU9683901A (en) 2002-04-22
NZ525402A (en) 2006-12-22
WO2002030980A8 (en) 2004-10-14
WO2002030980A3 (en) 2003-04-24
AU2001296839B2 (en) 2008-04-03
CA2425818A1 (en) 2002-04-18
US6432404B1 (en) 2002-08-13
JP2004532800A (ja) 2004-10-28
WO2002030980A2 (en) 2002-04-18
KR20030044001A (ko) 2003-06-02

Similar Documents

Publication Publication Date Title
MXPA03003322A (es) Subunidad de alfa de la beta2 integrina humana novedosa.
IL174756A0 (en) Human ??2 integrin alpha subunit
ZA200203316B (en) New use and novel n-azabicyclo-amide derivatives.
ZA200404306B (en) 3'-prodrugs of 2'-deoxy-beta-L-nucleosides.
IL156341A0 (en) 1,5 benzothiazepines and their use as antihyperlipidemics
MXPA03002273A (es) COMPOSICION DE CHAMPU Y BAnO CORPORAL QUE COMPRENDE MEZCLAS TERNARIAS DE AGENTES TENSIOACTIVOS CATIONICOS, ANIONICOS Y DE CONEXION Y METODOS PARA PREPARAR LA MISMA.
MXPA03004932A (es) 2-anilino-bencimidazoles sustituidos y su uso como inhibidores de nhe.
ZA200000394B (en) Detergent cosmetic composition and uses thereof.
EP1330168A4 (en) Lord UNTERHOSE
EP1210084A4 (en) PYRIDOMORPHINANS, THIENOMORPHINANS AND THEIR USE
MXPA03001826A (es) Derivados de arilpiperazina.
ZA200202530B (en) Fabric care composition.
EG23084A (en) Optically active 2,5-bisaryl-delta1-pyrrolines
DE50107204D1 (de) 8beta-substituierte-11beta-pentyl-und 11beta-hexyl-estra-1,3,5(10)-trienderivate
ZA200301162B (en) Gem-substituted alpha V beta 3 integrin antagonists.
MXPA03002900A (es) Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina.
ZA200109120B (en) Use of Arylalkanoylpyridazines.
AU5917801A (en) Novel integrin alpha subunit and uses thereof
AU2001296780A1 (en) 48120, 23479, and 46689, novel human hydrolases and uses thereof
HRP20020971A2 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-inhibitors
AU2001259178A1 (en) Integrin alpha subunit and uses thereof
Sensbach Gauguin's Cellist
ZA200106261B (en) "The rostering of staff".
ZA200103499B (en) "Support".
ZA200304306B (en) "Provision of graphic designs".

Legal Events

Date Code Title Description
FA Abandonment or withdrawal